Delving into the Latest Updates on Fluorothymidine F-18 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug, Diagnostic radiopharmaceuticals

Synonyms

+ [1]

Target-

Mechanism

PET imaging(Positron-emission tomography enhancers)

Therapeutic Areas

NeoplasmsImmune System DiseasesNervous System Diseases+ [2]

Active Indication

Acute Lymphoblastic LeukemiaBrain CancerMetastatic breast cancer

Inactive Indication

Acute Myeloid LeukemiaAnus NeoplasmsBrain metastases+ [19]

Originator Organization

National Cancer Institute

Active Organization

The Children's Hospital Corp.

Advanced Innovative Partners IncStartup

University of Pennsylvania

Inactive Organization

Mayo Clinic

Washington University School of Medicine

National Cancer Institute

+ [9]

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Structure

Molecular FormulaC10H13FN2O4

InChIKeyUXCAQJAQSWSNPQ-ZIVQXEJRSA-N

CAS Registry287114-80-1

This is a pilot study to assess a new methodology developed for High Grade Glioma (HGG). FMISO PET (Fluoromisonidazole-PET) allows researchers to study whether tumor cells lack oxygen (hypoxia). FLT PET (Fluorodeoxythymidine-PET) allows researchers to study the increase in the number of cells as a result of cell growth and cell division (proliferation). Tumors that have low oxygen levels and/or are dividing fast shall resist to standard cancer treatment. The study will compare FMISO PET and FLT PET imaging techniques with molecular biomarkers of hypoxia, angiogenesis, and cellular proliferation in tissue. proliferation).This information could help researchers develop new treatment techniques to better treat cancer.

Start Date01 Feb 2021

Sponsor / Collaborator

Weill Medical College of Cornell University

NCT04067115 / Active, not recruitingPhase 1/2IIT

SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin Administered as a 1-Hour Infusion in Ewing Sarcoma Patients in Combination With Low Dose Irinotecan and 3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging

This study evaluates the trabectedin and irinotecan in the treatment of Ewings sarcoma, with a EWS-FLI1 mutation. Patients will also receive an infusion of 18F-FLT in combination with a Positron Emission Tomography (PET) scan to help evaluate the effect of treatment.
Phase I was completed on 11/16/2022. Phase II is actively recruiting.

Start Date05 Jan 2021

Sponsor / Collaborator

Sarcoma Alliance for Research through Collaboration

[+3]

NCT03905538 / WithdrawnEarly Phase 1IIT

Evaluation of [18F]FLT PET/CT as an Early Predictor of Outcome in Pediatric Solid Tumors

The experimental [18F]FLT-PET/CT will be completed before initiation of chemotherapy at either diagnosis or initiation of salvage chemotherapy at relapse and prior to the third cycle (or month) of chemotherapy. Laboratory analysis and correlative radiology, as directed per clinical care based on the primary diagnosis, are required within 30 days of the baseline [18F]FLT PET/CT. Follow-up will comprise 24 months of standard practice treatment and follow up.

Start Date13 Aug 2019

Sponsor / Collaborator

The University of Texas Southwestern Medical Center

100 Clinical Results associated with Fluorothymidine F-18

Login to view more data

100 Translational Medicine associated with Fluorothymidine F-18

Login to view more data

100 Patents (Medical) associated with Fluorothymidine F-18

Login to view more data

31

Literatures (Medical) associated with Fluorothymidine F-18

01 Nov 2023·International journal of hematology

Hematopoiesis in the spleen after engraftment in unrelated cord blood transplantation evaluated by ¹⁸F-FLT PET imaging.

Article

Author: Hosono, Naoko ; Kiyono, Yasushi ; Yamauchi, Takahiro ; Tsujikawa, Tetsuya ; Okazawa, Hidehiko ; Araie, Hiroaki

Cord blood is an important donor source for allogeneic hematopoietic stem cell transplantation (allo-HSCT), with its unique composition and quality of hematopoietic cells. The proliferation site and potency of infused hematopoietic stem cells in humans may vary between stem cell sources. We investigated this possibility in a prospective, exploratory study to assess hematopoietic dynamics using the radiopharmaceutical 3'-deoxy-3'-¹⁸F-fluorothymidine (¹⁸F-FLT), a thymidine analog used in positron emission tomography imaging, before allo-HSCT and on days 50 and 180 after allo-HSCT. We evaluated 11 patients with hematological malignancies who underwent allo-HSCT [five with peripheral blood stem cell transplantation (PBSCT) and six with unrelated cord blood transplantation (UCBT)]. Before allo-HSCT, ¹⁸F-FLT uptake did not differ between the two groups. At day 50, ¹⁸F-FLT uptake in the spleen was significantly greater in the UCBT group than in the PBSCT group (p = 0.0043), with no difference in whole-body bone marrow. At day 180, the differences in spleen uptake had diminished, and there were no differences between groups in whole-body bone marrow or the spleen, except for the sternum. The persistence of splenic hematopoiesis after engraftment in the UCBT group may reflect the complex systemic homing and proliferation mechanisms of cord blood hematopoietic cells.

01 Nov 2023·Japanese journal of radiology

Evaluation of isocitrate dehydrogenase mutation in 2021 world health organization classification grade 3 and 4 glioma adult-type diffuse gliomas with 18F-fluoromisonidazole PET.

Article

Author: Oshima, Sonoko ; Sano, Kohei ; Nakamoto, Yuji ; Arakawa, Yoshiki ; Fushimi, Yasutaka ; Okuchi, Sachi ; Sakata, Akihiko ; Mineharu, Yohei ; Wang, Yang ; Hinoda, Takuya ; Tanji, Masahiro ; Nakajima, Satoshi ; Shimizu, Yoichi ; Yoshida, Kazumichi ; Ishimori, Takayoshi ; Otani, Sayo

PURPOSEThis study aimed to investigate the uptake characteristics of ¹⁸F-fluoromisonidazole (FMISO), in mutant-type isocitrate dehydrogenase (IDH-mutant, grade 3 and 4) and wild-type IDH (IDH-wildtype, grade 4) 2021 WHO classification adult-type diffuse gliomas.MATERIALS AND METHODSPatients with grade 3 and 4 adult-type diffuse gliomas (n = 35) were included in this prospective study. After registering ¹⁸F-FMISO PET and MR images, standardized uptake value (SUV) and apparent diffusion coefficient (ADC) were evaluated in hyperintense areas on fluid-attenuated inversion recovery (FLAIR) imaging (HIA), and in contrast-enhanced tumors (CET) by manually placing 3D volumes of interest. Relative SUV_max (rSUV_max) and SUV_mean (rSUV_mean), 10th percentile of ADC (ADC_10pct), mean ADC (ADC_mean) were measured in HIA and CET, respectively.RESULTSrSUV_mean in HIA and rSUV_mean in CET were significantly higher in IDH-wildtype than in IDH-mutant (P = 0.0496 and 0.03, respectively). The combination of FMISO rSUV_mean in HIA and ADC_10pct in CET, that of rSUV_max and ADC_10pct in CET, that of rSUV_mean in HIA and ADC_mean in CET, were able to differentiate IDH-mutant from IDH-wildtype (AUC 0.80). When confined to astrocytic tumors except for oligodendroglioma, rSUV_max, rSUV_mean in HIA and rSUV_mean in CET were higher for IDH-wildtype than for IDH-mutant, but not significantly (P = 0.23, 0.13 and 0.14, respectively). The combination of FMISO rSUV_mean in HIA and ADC_10pct in CET was able to differentiate IDH-mutant (AUC 0.81).CONCLUSIONPET using ¹⁸F-FMISO and ADC might provide a valuable tool for differentiating between IDH mutation status of 2021 WHO classification grade 3 and 4 adult-type diffuse gliomas.

01 Feb 2023·Journal of Magnetic Resonance Imaging

Breast PET/MRI Hybrid Imaging and Targeted Tracers

Review

Author: Romeo, Valeria ; Pinker, Katja ; Helbich, Thomas H.

The recent introduction of hybrid positron emission tomography/magnetic resonance imaging (PET/MRI) as a promising imaging modality for breast cancer assessment has prompted fervent research activity on its clinical applications. The current knowledge regarding the possible clinical applications of hybrid PET/MRI is constantly evolving, thanks to the development and clinical availability of hybrid scanners, the development of new PET tracers and the rise of artificial intelligence (AI) techniques. In this state‐of‐the‐art review on the use of hybrid breast PET/MRI, the most promising advanced MRI techniques (diffusion‐weighted imaging, dynamic contrast‐enhanced MRI, magnetic resonance spectroscopy, and chemical exchange saturation transfer) are discussed. Current and experimental PET tracers (18F‐FDG, 18F‐NaF, choline, 18F‐FES, 18F‐FES, 89Zr‐trastuzumab, choline derivatives, 18F‐FLT, and 68Ga‐FAPI‐46) are described in order to provide an overview on their molecular mechanisms of action and corresponding clinical applications. New perspectives represented by the use of radiomics and AI techniques are discussed. Furthermore, the current strengths and limitations of hybrid PET/MRI in the real world are highlighted.Evidence Level2Technical EfficacyStage 2

100 Deals associated with Fluorothymidine F-18

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Fluorothymidine F-18	-	DB14930

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Laryngeal Neoplasms	Phase 2	US	National Cancer Institute	01 Mar 2008
Mouth Neoplasms	Phase 2	US	National Cancer Institute	01 Mar 2008
Squamous Cell Carcinoma of Head and Neck	Phase 2	US	National Cancer Institute	01 Mar 2008
Brain Cancer	Phase 1	CA	AHS Cancer Control Alberta	20 Mar 2009
Gastrointestinal Neoplasms	Phase 1	CA	AHS Cancer Control Alberta	20 Mar 2009
Lymphoma	Phase 1	CA	AHS Cancer Control Alberta	20 Mar 2009
Neuroendocrine Tumors	Phase 1	CA	AHS Cancer Control Alberta	20 Mar 2009
Breast Cancer	Preclinical	-	Merck Sharp & Dohme Corp.	08 Apr 2010
Brain Cancer	Preclinical	CA	AHS Cancer Control Alberta	20 Mar 2009
Oropharyngeal Neoplasms	Preclinical	US	National Cancer Institute	01 Mar 2008

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00572728 (CTgov)	Phase 2	Locally advanced breast cancer \| Invasive Mammary Carcinoma \| Breast Cancer 3	90	PET+18F-FLT	xwjbvuqjbr(iblzugftvk) = kcabjhmlze shkcanglzp (joohozzliv, gfqdebspvy - lcizwbmfmo) View more	-	20 Jan 2016
JPRN-UMIN000009329 (ASCO2015)	Phase 2	Stomach Cancer	20	<sup>18</sup>F-fluorothymidine (<sup>18</sup>F-FLT) (18F-FLT PET/CT)	deryevxhqy(tlozpoxxsv) = agctbqomhq zhsvumufbc (ghcfcdmzad )	-	20 May 2015
NCT00979810 (CTgov)	Not Applicable	High grade glioma	11	18F-FLT PET Scan	mkahbexmsv(nzlucerjxy) = ngbzzfkphb ptgtguhskc (mjcyfrgovj, jcirfwlztp - fwyvsczluf) View more	-	17 Dec 2020
NCT01399658 (CTgov)	Phase 2	Uterine Cervical Cancer \| Vulvar Neoplasms \| Vagina Carcinoma	93	Image-guided brachytherapy+3'-Deoxy-3'-18f-Fluorothymidine	oqprjnrvos(hjekwreevc) = uxapqpphuw quxsjkuoto (unrgiefxdq, ttvisgidyg - pvhaumqejx) View more	-	02 Mar 2022
NCT00721799 (Pubmed \| J Nucl Med)	Phase 2	Head and Neck Neoplasms	8	3'-deoxy-3'-<sup>18</sup>F-fluorothymidine (<sup>18</sup>F-FLT) (Head and neck cancer patients)	qjsmkmabwi(xcmjctzthr) = hecvbcxfdx ojndcldtxd (jxyrfiuawp ) View more	-	01 Jul 2009
ISC2019	Not Applicable	Ischemic stroke	-	F-18-fluorothymidine (Rats subjected to transient middle cerebral artery occlusion (MCAO))	dvarvocvys(uuwaveiyoe) = cerebral FLT binding activity gradually declined from post MCAO day 7 to day 28 in the infarcted brain buqwvgrzqe (nrihbkeisq ) View more	-	01 Feb 2019
NCT00572728 (ACRIN 6688, Pubmed \| J Nucl Med)	Phase 2	Breast Cancer Neoadjuvant	90	3'-Deoxy-3'-18F-Fluorothymidine	-	-	01 Nov 2015
NCT00572728 (ACRIN 6688, Pubmed \| J Nucl Med)	Phase 2	Breast Cancer Neoadjuvant	90	Neoadjuvant Chemotherapy	-	-	01 Nov 2015
NCT00721799 (CTgov)	Phase 2	Laryngeal Neoplasms \| Oropharyngeal Neoplasms \| Mouth Neoplasms \| Squamous Cell Carcinoma of Head and Neck	33	18F-Fluorothymidine PET scan	hayqhfsahn(pmzafrbsts) = mtxccldkin pzhvnpifgd (olhvdnmovo, zvradgfqjn - laduqtkaam) View more	-	03 Oct 2017
NCT00847509 (CTgov)	Not Applicable	Lung Cancer \| Head and Neck Neoplasms	49	[F-18]FLT	fjpuxnvvtv(emazwhsxcw) = xzfblhmrty xgawijgllm (uweulwiqmp, fhksqjzcgz - sdnpemtmfb) View more	-	27 Sep 2013